Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study

被引:5
|
作者
Okauchi, Shinichiro [1 ]
Numata, Takeshi [2 ,3 ]
Nawa, Takeshi [4 ,5 ]
Ichimura, Hideo [4 ,5 ]
Saito, Takefumi [6 ]
Hayashihara, Kenji [6 ]
Yamada, Hideyasu [7 ]
Satoh, Hiroaki [1 ]
Endo, Takeshi [2 ,3 ]
Inage, Yoshihisa [2 ,3 ]
Kaburagi, Takayuki [8 ]
Kiyoshima, Moriyuki [8 ]
Yamada, Yutaka [8 ]
Tamura, Tomohiro [8 ]
Saito, Kazuhito [9 ,10 ]
Inagaki, Masaharu [9 ,10 ]
Hizawa, Nobuyuki [11 ]
Sato, Yukio [11 ]
Shiozawa, Toshihiro [11 ]
Sekine, Ikuo [11 ]
Ishikawa, Hiroichi [12 ,13 ]
Kurihima, Koichi [12 ,13 ]
Sakai, Mitsuaki [12 ,13 ]
Kamiyama, Koichi [14 ]
Kimura, Masaki [14 ]
Kikuchi, Norihiro [15 ]
Nakamura, Hiroyuki [16 ,17 ]
Furukawa, Kinya [16 ,17 ]
Kodama, Takahide [18 ]
Miyazaki, Kunihiko [18 ]
Yamashita, Takaaki [19 ]
Hayashi, Shigen [20 ]
Funayama, Yasunori [21 ]
Nomura, Akihiro [20 ]
机构
[1] Univ Tsukuba, Mito Kyodo Gen Hosp, Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan
[2] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan
[3] Mito Med Ctr, Div Thorac Surg, Mito, Ibaraki, Japan
[4] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan
[5] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan
[6] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan
[7] Univ Tsukuba, Div Resp Med, Hitachinaka Med Ctr, Mito, Ibaraki, Japan
[8] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan
[9] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan
[10] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan
[11] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan
[12] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan
[13] Tsukuba Med Ctr Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan
[14] Tsukuba Kinen Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan
[15] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan
[16] Tokyo Med Univ, Ibaraki Med Ctr, Div Resp Med, Ami, Ibaraki, Japan
[17] Tokyo Med Univ, Ibaraki Med Ctr, Div Thorac Surg, Ami, Ibaraki, Japan
[18] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan
[19] JA Toride Med Ctr, Div Resp Med, Toride, Japan
[20] Seinan Med Ctr, Div Resp Med, Sakai, Osaka, Japan
[21] Tsukuba Gakuen Gen Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan
关键词
Clinical practice; alectinib; non-small cell lung cancer; anaplastic lymphoma kinase fusion gene mutation; chemotherapy; KINASE INHIBITION; TYROSINE KINASE; CRIZOTINIB; THERAPY; CHEMOTHERAPY; ALECTINIB; SURVIVAL;
D O I
10.21873/anticanres.14029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 50 条
  • [31] A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC
    O'Sullivan, H.
    Conroy, M.
    Goggin, C.
    Carroll, H.
    Kelly, C.
    Kamel, D.
    Carney, D.
    Blazkova, S.
    Power, D.
    Higgins, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S666 - S666
  • [32] SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC
    Dardaei, Leila
    Wang, Hui Qin
    Singh, Manrose
    Fordjour, Paul
    Yoda, Satoshi
    Kerr, Grainne
    Liang, Jinsheng
    Cao, Yichen
    Chen, Yan
    Gainor, Justin
    Friboulet, Luc
    Dagogo-Jack, Ibiayi
    Myers, David
    Labrot, Emma
    Ruddy, David
    Parks, Melissa
    Lee, Dana
    DiCecca, Richard
    Moody, Susan
    Hao, Huaixiang
    Mohseni, Morvarid
    LaMarche, Matthew
    Williams, Juliet
    Hoffmaster, Keith
    Caponigro, Giordano
    Shaw, Alice
    Hata, Aaron
    Benes, Cyril
    Li, Fang
    Engelman, Jeffrey
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [33] Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
    Takeyasu, Yuki
    Okuma, Hitomi S.
    Kojima, Yuki
    Nishikawa, Tadaaki
    Tanioka, Maki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Arakawa, Ayumu
    Mori, Taisuke
    Sunami, Kuniko
    Kubo, Takashi
    Kohno, Takashi
    Akihiko, Yoshida
    Yamamoto, Noboru
    Yonemori, Kan
    JCO PRECISION ONCOLOGY, 2021, 5 : 756 - 766
  • [34] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [35] Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome
    Hida, T.
    Lydon, C.
    Hatabu, H.
    Johnson, B.
    Awad, M.
    Nishino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S473 - S474
  • [36] Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
    Cha, Yoon Jin
    Kim, Hye Ryun
    Shim, Hyo Sup
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [37] PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN JAPANESE PATIENTS WITH ADVANCED, ALK-REARRANGED NSCLC AND OTHER TUMORS HARBORING GENETIC ALK ALTERATIONS
    Seto, Takashi
    Murakami, Haruyasu
    Hirai, Fumihiko
    Horiike, Atsushi
    Takahashi, Toshiaki
    Suenaga, Naoko
    Tajima, Takeshi
    Tokushige, Kota
    Boral, Anthony
    Robson, Matthew
    Nishio, Makoto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S595 - S596
  • [38] Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?
    Thai, A. A.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2160 - 2162
  • [39] Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint
    Zhou, Fei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 485 - 488
  • [40] Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
    Yoon Jin Cha
    Hye Ryun Kim
    Hyo Sup Shim
    Journal of Translational Medicine, 14